Substance / Medication

Triamcinolone diacetate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

104 trials linked to this intervention

104
Total Trials
34
Recruiting
23
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Occupational exposure to beryllium and cancer risk: a review of the epidemiologic evidence.
Boffetta Paolo, Fryzek Jon P, Mandel Jack S · Crit Rev Toxicol · 2012
PMID: 22276590Meta-Analysis
Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis.
Schaeffer Tammi H, Khatri Vaishali, Reifler Liza M et al. · Acad Emerg Med · 2012
PMID: 22320362Meta-Analysis
Systematic review: Progression of beryllium sensitization to chronic beryllium disease.
Seidler A, Euler U, Müller-Quernheim J et al. · Occup Med (Lond) · 2012
PMID: 22705916Meta-Analysis
Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.
Maier Lisa A, Barkes Briana Q, Mroz Margaret et al. · Respir Med · 2012
PMID: 22974830RCTFull text (PMC)
Plasmapheresis and RATG-induced serum sickness.
Christiaans Maarten H L, van Hooff Johannes P · Transplantation · 2006
PMID: 16436978RCT
Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms.
León Guillermo, Herrera María, Segura Álvaro et al. · Toxicon · 2013
PMID: 24055551Review
Investigations on the polymorphism and pseudopolymorphism of triamcinolone diacetate.
Suitchmezian Viktor, Jess Inke, Näther Christian · Int J Pharm · 2006
PMID: 16828995Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Triamcinolone diacetate (substance)
SNOMED CT
116595005
UMLS CUI
C0040867

Clinical Data

This intervention maps to 34 entities in the Healos knowledge graph.

20
Conditions
7
Biomarkers
5
Specialists
0
Symptoms
104
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.